â??Study of Kuka cough lozenges in Kasa (acute coughing and throat irritation)â??

Phase 2

Completed

• Conditions: Health Condition 1: J069- Acute upper respiratory infection,unspecified

• Registration Number: CTRI/2019/12/022588
• Lead Sponsor: Multani Pharmaceuticals Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 January 2023

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 120

Inclusion Criteria

1. Males and females with a history of acute cough due to any cause except those listed in exclusion criteria.

2. Throat irritation for <1 week duration, who will be able to comply with the study requirements

3. Patients having a cough score of 0, 1 or 2 during day time (as per Day Time Cough Scale described under end points)

4. Patients willing and able to provide signed ICF prior to study

Exclusion Criteria

1. Participants with a history of acute lower respiratory tract infections such as pneumonia, bronchitis whooping cough, chronic obstructive pulmonary disease/asthma, tuberculosis, systemic bacterial infections for which specific drug therapy will be required;

2. Any underlying lung pathology such as lung abscess or cystic fibrosis

3. Individuals with a history of myocardial infarction within 4 weeks prior to enrollment;

4. Individuals with a history of Parkinsonâ??s disease and who were on monoamine oxidase inhibitors.

5. Individuals with any psychiatric illness which may impair the ability to provide written ICF.

6. Individuals participating in any other clinical trial.

7. Pregnant or lactating females.

8. Those who are under study treatment or any other condition due to which individuals are deemed unsuitable by the investigator for reason(s) not specifically stated in the exclusion criteria

9. Alcohol, smoke, and drug abusers will be excluded.

Study & Design

• Study Type: Interventional
• Study Design: Not specified